Peter Milner

Peter Milner has extensive work experience in the biopharmaceutical industry. Peter started their career as the Co-Founder, CEO, and later President of ARYx Therapeutics from 1997 to 2010. Peter then served as a Co-Founder and Member of the Board of Directors at Optivia Biotechnology from 2007 to 2018. In 2007, they also became a Member of the Board of Directors at California Healthcare Institute, where they worked until 2015. From 2011 to 2017, Peter held various roles, including Executive Chairman at Armetheon, Member of the Board of Directors at SinuSys Corp., and Member of the Board of Directors at Heart Metabolics. Peter served as the Chief Medical Officer at Retrotope Inc. from 2015 and as the CEO at Renexxion from 2016. Peter also worked as a Director at Solstice from 2013 to 2015. In 2017, Peter joined Espero BioPharma as a Director, where they worked until 2019. Overall, Peter Milner has amassed a wealth of experience in leadership, executive, and board positions in the biopharmaceutical industry.

Peter Milner attended the University of Liverpool from 1974 to 1981, where they obtained a BSc (Hons) MB ChB degree in Medicine.